PALATIN TECHNOLOGIES INC
Palatin is a biopharmaceutical company developing medicines that modulate the melanocortin receptor system. Its programs focus primarily on MC4R agonists for obesity, including rare neuroendocrine diseases and other MC4R pathway disorders, and also include receptor agonists for inflammatory and autoimmune diseases. Product candidates include a long-acting peptide intended for once-weekly injection, an oral small molecule, and peptides for ocular and other inflammatory conditions. Palatin uses drug-design and development capabilities to discover and optimize peptide, peptide-mimetic, and small-molecule compounds. Palatin seeks to advance selected candidates through development and to partner with pharmaceutical and biotechnology companies through collaborations, licenses, and other arrangements. It can receive upfront and research payments, development and regulatory milestones, and royalties under these agreements. Certain retinal-disease compounds are licensed to Boehringer Ingelheim, and Palatin has sublicensed PL9643 for dry eye disease to Altanispac Labs. Vyleesi, its FDA-approved treatment for premenopausal women with hypoactive sexual desire disorder, was acquired by Cosette in December 2023. Palatin is headquartered in Cranbury, New Jersey.
No enriched coverage for $PTN in the last 7 days.
No SEC Form 4 filings for $PTN in the last 30 days.
See all $PTN insider activity →Palatin Technologies (PTN) reported $13.2M in FY 2026 revenue, up from zero, with a net loss of $8.4M. Key revenue sources included Boehringer Ingelheim ($9.4M) and Altanispac ($3.8M). Cash reserves grew to $7.5M. The company plans to advance MC4R agonist therapies for obesity, with clinical trials expected in 2027. Management expressed concerns about liquidity, stating existing cash may not last 12 months.
Palatin Technologies reported $13.2M in licensing revenue and a net loss of $8.4M for fiscal 2026. The company expressed concerns about its ability to continue as a going concern due to operating losses and limited cash. It is focused on advancing MC4R agonist programs for rare obesity disorders, relying on milestone-dependent licensing revenue.
Palatin Technologies reported a wider Q4 loss of $4.36M ($1.11 per share) vs. $2.23M ($2.73 per share) a year ago, driven by higher operating expenses. Revenue was $0.3M, up from zero. Shares fell 6.34% to $9.45 on Nasdaq.
Recent PTN coverage spans earnings, financial news and sector analysis.
Earnings miss and limited cash raise pressure the stock lower.
Going‑concern risk and widening loss pressure the stock lower.
Earnings miss and higher expenses likely pressure the stock lower.
Earnings show modest top‑line growth but loss remains sizable; market may price in a slight downside.
The earnings release shows modest revenue and a cash shortfall, suggesting near‑term financing pressure, while the pipeline announcements could support upside if funding is secured.
AlphAI scores every news story that mentions PTN with an AI model for sentiment and relevance, and aggregates insider trades from PALATIN TECHNOLOGIES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Palatin Technologies (PTN) reported $13.2M in FY 2026 revenue, up from zero, with a net loss of $8.4M. Key revenue sources included Boehringer Ingelheim ($9.4M) and Altanispac ($3.8M). Cash reserves grew to $7.5M. The company plans to advance MC4R agonist therapies for obesity, with clinical trials expected in 2027. Management expressed concerns about liquidity, stating existing cash may not last 12 months.
3 min readPalatin Technologies reported $13.2M in licensing revenue and a net loss of $8.4M for fiscal 2026. The company expressed concerns about its ability to continue as a going concern due to operating losses and limited cash. It is focused on advancing MC4R agonist programs for rare obesity disorders, relying on milestone-dependent licensing revenue.
1 min readPalatin Technologies reported a wider Q4 loss of $4.36M ($1.11 per share) vs. $2.23M ($2.73 per share) a year ago, driven by higher operating expenses. Revenue was $0.3M, up from zero. Shares fell 6.34% to $9.45 on Nasdaq.
1 min readPalatin Technologies reported $13.2M in fiscal 2026 revenue, up from collaborations, with a narrowed net loss of $8.4M. The company advanced multiple obesity programs toward clinical trials but requires additional funding for operations, according to its SEC filing.
1 min readPalatin Technologies reported fiscal 2026 revenue of $13.2M, including $9.4M from Boehringer Ingelheim. The company plans Phase 1 trials for MC4R obesity treatments in 2027-2028. Cash reserves were $7.5M as of June 30, 2026, with additional funding needed for development. PTN is exploring partnerships for PL8177 and diabetic nephropathy programs.
2 min readPalatin Technologies (PTN), valued at $20M, is developing melanocortin-receptor drugs for rare obesity, following Rhythm Pharmaceuticals (RYTM) and Neurocrine Biosciences' successes in the space. PTN's programs aim to improve efficacy and tolerability, with clinical trials expected to start in late 2026 and 2027. The market's validation of MC4R targets and rare-obesity drugs could significantly impact PTN's valuation.
2 min readThe article says rare endocrine and obesity assets have drawn about $2.9B (Neurocrine to acquire Soleno) and $10.0B (Vertex to acquire Crinetics) in four months. It highlights Rhythm’s IMCIVREE revenue of $71.3M in Q2 2026 and discusses Palatin Technologies (PTN) developing next-gen MC4R-selective candidates with IND targets in Q4 2026 and H1 2027.
7 min readPALATIN TECHNOLOGIES INC (PTN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On July 28, 2026, Palatin Technologies, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the following: (1) election of directors (“Item 1”), (2) ratification
2 min read
